Workshop reportClinical trial preparedness in facioscapulohumeral muscular dystrophy: Clinical, tissue, and imaging outcome measures 29-30 May 2015, Rochester, New York

•Many national registries now exist facilitating patient access to trials.•New functional and patient reported outcome measure is being validated.•More research is required to establish reliable tissue and serum biomarkers.•Longitudinal muscle MRI studies suggest that imaging is a useful biomarker in FSHD.•Electrical impedance myography is reliable in certain muscle groups.